HUIZENGA THEODORE ALAN (SVP, Chief Accounting Officer) sold 1.9% of their position (967.00 shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $40.7K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/4/2025ACC: 0000950170-25-032764
Officer· SVP, Chief Accounting Officer
Since Mar 2026
+13.92K
Net shares
Net buyer
$46.8K
Total sold
1
Open market trades
0B · 1S
4
Total transactions
15.02K acquired · 1.11K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
+9.39K
Price / share
—
Trade value
—
% of position
22.4%
3/1/2025
41.84K→51.23K
Common Stock
Direct
Shares
−967.00
Price / share
$42.10
Trade value
$40.71K
% of position
1.9%
3/3/2025
51.23K→50.27K
Common Stock
Direct
Shares
−141.00
Price / share
$42.92
Trade value
$6.05K
% of position
0.3%
3/3/2025
50.27K→50.12K
Total
Net shares
+8.28K
Net value
-$46.76K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/1/2025 | A · Award | +9.39K | — | — | 22.4% | 41.84K | 51.23K |
| Common Stock Direct | 3/3/2025 | S · Sale | −967.00 | $42.10 | $40.71K | 1.9% | 51.23K | 50.27K |
| Common Stock Direct | 3/3/2025 | F · Tax Withholding | −141.00 | $42.92 | $6.05K | 0.3% | 50.27K | 50.12K |
| Total | +8.28K | -$46.76K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
5.63K shares
Shares
+5.63K
Strike price
42.92
Held after
5.63K
Exercisable
—
3/1/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock5.63K shares | 3/1/2025 | A · Award | +5.63K | 42.92 | — | 5.63K |